WO2013184037A3 - Composition pharmaceutique antibactérienne - Google Patents

Composition pharmaceutique antibactérienne Download PDF

Info

Publication number
WO2013184037A3
WO2013184037A3 PCT/RU2013/000467 RU2013000467W WO2013184037A3 WO 2013184037 A3 WO2013184037 A3 WO 2013184037A3 RU 2013000467 W RU2013000467 W RU 2013000467W WO 2013184037 A3 WO2013184037 A3 WO 2013184037A3
Authority
WO
WIPO (PCT)
Prior art keywords
preservative
antioxidant
azithromycin
ascorbate
pharmaceutical composition
Prior art date
Application number
PCT/RU2013/000467
Other languages
English (en)
Russian (ru)
Other versions
WO2013184037A2 (fr
Inventor
Борис Викторович ВИОЛИН
Сергей Вячеславович СЕМЁНОВ
Дмитрий Владимирович ПРИСТЕНСКИЙ
Александр Андреевич АНИСЬКОВ
Original Assignee
Общество С Ограниченной Ответственностью "Вик - Здоровье Животных"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" filed Critical Общество С Ограниченной Ответственностью "Вик - Здоровье Животных"
Priority to EA201400830A priority Critical patent/EA027144B1/ru
Priority to BR112014025017A priority patent/BR112014025017A2/pt
Priority to CN201380019631.1A priority patent/CN104470502B/zh
Priority to US14/395,483 priority patent/US20150126466A1/en
Priority to IN2016MUN2014 priority patent/IN2014MN02016A/en
Priority to EP13800655.6A priority patent/EP2859885A4/fr
Priority to MX2014011345A priority patent/MX361596B/es
Publication of WO2013184037A2 publication Critical patent/WO2013184037A2/fr
Publication of WO2013184037A3 publication Critical patent/WO2013184037A3/fr
Priority to US15/792,970 priority patent/US20180042953A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte au domaine de la médecine vétérinaire et de la médecine, et peut être utilisée afin de prévenir et de traiter des infections bactériennes. Le but de la présente invention est d'élaborer une préparation à base d'azithromycine sous forme de solution, ayant un large spectre d'action antimicrobienne, et sous forme d'une solution à injecter prête à l'emploi par administration non seulement intraveineuse mais aussi intramusculaire, sous-cutanée, intra-utérine ou intra-mammaire. Cette composition pharmaceutique antibactérienne comprend de l'azithromycine, des solvants et/ou des co-solvants, un conservateur et un antioxydant. L'antioxydant consiste en de l'acide ascorbique ou en de l'ascorbate de sodium ou en de l'ascorbate de calcium ou de l'ascorbate de palmitoyl ou du 4-méthyl-2,6-ditertbutylphénol ou tertbutylhydroquinone ou du 2,4,5-trihydroxybutyrophénone ou du métabisulfite de sodium ou de l'alpha-tocophérol ou de la thioglycérine ou leur combinaison; le conservateur consiste en de l'alcool benzylique, du parabène, du chloretone ou leur combinaisons, selon les proportions suivantes des composants en % en poids : azithromycine : 5-50%; antioxydant : 0,1-0,2%; conservateur 1-2%; le reste se composant de solvants.
PCT/RU2013/000467 2012-06-08 2013-06-06 Composition pharmaceutique antibactérienne WO2013184037A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EA201400830A EA027144B1 (ru) 2012-06-08 2013-06-06 Антибактериальная инъекционная фармацевтическая композиция
BR112014025017A BR112014025017A2 (pt) 2012-06-08 2013-06-06 Composição farmacêutica injetável antibacteriana
CN201380019631.1A CN104470502B (zh) 2012-06-08 2013-06-06 抗细菌药物组合物
US14/395,483 US20150126466A1 (en) 2012-06-08 2013-06-06 Antibacterial pharmaceutical composition
IN2016MUN2014 IN2014MN02016A (fr) 2012-06-08 2013-06-06
EP13800655.6A EP2859885A4 (fr) 2012-06-08 2013-06-06 Composition pharmaceutique antibactérienne
MX2014011345A MX361596B (es) 2012-06-08 2013-06-06 Composición farmacéutica inyectable antibacterial.
US15/792,970 US20180042953A1 (en) 2012-06-08 2017-10-25 Antibacterial injectable pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2012123616/15A RU2512683C2 (ru) 2012-06-08 2012-06-08 Антибактериальная инъекционная фармацевтическая композиция
RU2012123616 2012-06-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/395,483 A-371-Of-International US20150126466A1 (en) 2012-06-08 2013-06-06 Antibacterial pharmaceutical composition
US201715630151A Continuation 2012-06-08 2017-06-22

Publications (2)

Publication Number Publication Date
WO2013184037A2 WO2013184037A2 (fr) 2013-12-12
WO2013184037A3 true WO2013184037A3 (fr) 2014-04-03

Family

ID=49712781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2013/000467 WO2013184037A2 (fr) 2012-06-08 2013-06-06 Composition pharmaceutique antibactérienne

Country Status (9)

Country Link
US (1) US20150126466A1 (fr)
EP (1) EP2859885A4 (fr)
CN (1) CN104470502B (fr)
BR (1) BR112014025017A2 (fr)
EA (1) EA027144B1 (fr)
IN (1) IN2014MN02016A (fr)
MX (1) MX361596B (fr)
RU (1) RU2512683C2 (fr)
WO (1) WO2013184037A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2563826C1 (ru) * 2014-08-21 2015-09-20 Общество с ограниченной ответственностью "Научно-внедренческий центр Агроветзащита" Инъекционная антибактериальная фармацевтическая композиция
CN108721209A (zh) * 2017-04-20 2018-11-02 广东东阳光药业有限公司 一种兽用阿奇霉素注射剂
RU2666607C1 (ru) * 2017-05-03 2018-09-11 Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" Способ повышения стабильности инъекционной фармацевтической композиции

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1613453A (zh) * 2003-11-04 2005-05-11 山西亚宝药业集团股份有限公司 一种阿奇霉素注射液及制备方法
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
RU2304962C2 (ru) * 2000-02-16 2007-08-27 Мериал Лимитед Фармацевтические и ветеринарные пастообразные композиции
RU2327453C2 (ru) * 2006-03-28 2008-06-27 Управление ветеринарии Курской области Состав для терапии и профилактики инфекционных заболеваний животных

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1205338A (zh) * 1998-05-08 1999-01-20 刘万忠 阿奇霉素水溶性盐的合成新方法及其在医药上的用途
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
HUP0402291A2 (hu) * 2001-10-18 2005-03-29 Teva Pharmaceutical Industries Ltd. Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
US7064104B2 (en) 2003-06-13 2006-06-20 The Procter & Gamble Company Methods of managing the symptoms of premenstrual syndrome
US20070185194A1 (en) 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
EP1648473B1 (fr) 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Dose unique a dissolution rapide d'azithromycine
US20050101547A1 (en) 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US20090318375A1 (en) 2005-06-08 2009-12-24 Hanmi Pharm Co., Ltd Crystalline Azithromycin L-Malate Monohydrate and Pharmaceutical Composition Containing Same
US7795231B2 (en) * 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
CN101244076B (zh) * 2008-03-24 2012-10-31 南京华威医药科技开发有限公司 一种阿奇霉素眼用药物组合物
CN101683532A (zh) * 2008-09-25 2010-03-31 武汉诺安药业有限公司 含玻璃酸或其盐的眼用复方药物制剂
CN101874808A (zh) * 2010-05-12 2010-11-03 邓学峰 阿奇霉素组合药物
CN102283799B (zh) * 2011-08-17 2013-07-31 北京乐维生物技术有限公司 一种阿奇霉素凝胶型滴眼液及其制备工艺

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2304962C2 (ru) * 2000-02-16 2007-08-27 Мериал Лимитед Фармацевтические и ветеринарные пастообразные композиции
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
CN1613453A (zh) * 2003-11-04 2005-05-11 山西亚宝药业集团股份有限公司 一种阿奇霉素注射液及制备方法
RU2327453C2 (ru) * 2006-03-28 2008-06-27 Управление ветеринарии Курской области Состав для терапии и профилактики инфекционных заболеваний животных

Also Published As

Publication number Publication date
MX2014011345A (es) 2015-05-11
EA201400830A1 (ru) 2014-11-28
CN104470502A (zh) 2015-03-25
RU2012123616A (ru) 2013-12-20
EP2859885A2 (fr) 2015-04-15
MX361596B (es) 2018-12-11
RU2512683C2 (ru) 2014-04-10
EP2859885A4 (fr) 2016-05-25
IN2014MN02016A (fr) 2015-08-07
WO2013184037A2 (fr) 2013-12-12
CN104470502B (zh) 2018-11-06
EA027144B1 (ru) 2017-06-30
BR112014025017A2 (pt) 2017-08-22
US20150126466A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
BR112018075998A2 (pt) composições antifúngicas sinérgicas e métodos das mesmas
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
AR098576A1 (es) Producto farmacéutico
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
BR112014005700A2 (pt) composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112016006589A2 (pt) composição, e composição de vacina
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
WO2015157559A3 (fr) Saxitoxines 10',11'-modifiées pour le traitement de la douleur
WO2009046314A3 (fr) Analogues de la moénomycine, procédés de synthèse et utilisations de ceux-ci
AR081611A1 (es) Combinaciones de principios activos acaricidas y/o insecticidas
NZ596628A (en) Ketolide compounds having antimicrobial activity
WO2012093234A3 (fr) Arabinogalactanes sulfates, apiogalacturonanes et heteroglycanes sulfates pour le traitement des maladies causees par les virus influenza
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
WO2013184037A3 (fr) Composition pharmaceutique antibactérienne
MX341300B (es) Composiciones para el tratamiento de ulceras perifericas de varios origenes.
NI201900063A (es) Amidas aromáticas de ácido carboxílico
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
BR112015006464A2 (pt) composição farmacêutica compreendendo rebamipida
MX2014013091A (es) Composicion farmaceutica.
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201400830

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/011345

Country of ref document: MX

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13800655

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14395483

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014025017

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014025017

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141007